Sort by

Send to

Choose Destination

Search results

Items: 4


Pharmacogenomics: An evolving clinical tool for precision medicine.

Hockings JK, Pasternak AL, Erwin AL, Mason NT, Eng C, Hicks JK.

Cleve Clin J Med. 2020 Feb;87(2):91-99. doi: 10.3949/ccjm.87a.19073. Review.


Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.

Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM.

Oncologist. 2017 Feb;22(2):144-151. doi: 10.1634/theoncologist.2016-0195. Epub 2017 Feb 8.


Budget impact analysis of CYP2C19-guided voriconazole prophylaxis in AML.

Mason NT, Bell GC, Quilitz RE, Greene JN, McLeod HL.

J Antimicrob Chemother. 2015 Nov;70(11):3124-6. doi: 10.1093/jac/dkv224. Epub 2015 Aug 1.


Budget Impact Analysis of CYP2C19 Genotyping to Target Voriconazole Prophylaxis During Induction-Consolidation Therapy in Acute Myeloid Leukemia (AML) in The United States.

Mason NT, Bell GC, McLeod HL.

Value Health. 2014 Nov;17(7):A621-2. doi: 10.1016/j.jval.2014.08.2203. Epub 2014 Oct 26. No abstract available.

Supplemental Content

Loading ...
Support Center